İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025

The Long-Term Effects on Recurrence and Progression of Bladder Tumors of Chemotherapeutic Agents Used After Transurethral Resection

Endoüroloji Bülteni (Türk Endoüroloji Derneği)

YÖKSİS OpenAlex Açık erişim · diamond TR Index Atıf 0 Yüzdelik 21.1% FWCI 0.0
Yıl
2025
ISSN
2148-0532
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Objective: Early single dose chemotherapy may have a reducing effect on recurrence and progression. In this study, we aimed to compare non-muscle invasive patients diagnosed with bladder cancer who did not receive early single dose chemotherapy and those who received intravesical Epirubicin or Gemcitabine in terms of recurrence and progression. Material and Methods: 116 patients were followed up for 48 months (May 2020-June 2022) with diagnosis of primary non-invasive bladder cancer. After transurethral resection of the bladder, patients were followed up with 3 groups: who received intravesical epirubicin, who received gemcitabine, who did not receive any chemotherapeutic agent. Results: The mean age was 63. There were no statistically significant difference in age and, body mass index. Recurrence was determined 57.1% (n=20), 40% (n=18), and 41.7% (n=15) (p=0.263) of the patients, respectively who were not administered any intravesical agent, were administered Epirubicin and, Gemcitabine. While recurrence rates were observed 50%, 25%, 0% (p=0.177) respectively, in low-risk, no progression was detected. In intermediate risk group, 66.7%, 33.3%, 42.8% (p=0.378) recurrence, and 33.3%, 22.7%, 6.7% (p=0.282) progression were detected, respectively. High-risk group, recurrence was found in 56%, 64.2%, 56.2% (p=0.866) of the patients and progression 8%, 14.3%, 6.3% (p=0.723) respectively. In low-grade group, 35.7%, 42.9%, 21.4% (p=0.045) recurrence, and 16.6%, 12.1%, and 4.3% (p=0.164) progression were determined , respectively. In the high-grade group, 58.8%, 50%, 69.2% (p=0.982) recurrence, 5.9%, 16.6% and 7.7% (p=0.581) progression were detected, respectively. Conclusion: These findings demonstrated that intravesical chemotherapeutics can delay or prevent recurrence and progression, should therefore be administered in early postoperative period. Gemcitabine is not in widespread use and has been found to be a good alternative.

Konular

  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Urological Disorders and Treatments

Birincil konu Bladder and Urothelial Cancer Treatments

Yazarlar

  1. EMRE KIRAÇ
  2. ESAT KORĞALI SİVAS CUMHURİYET ÜNİVERSİTESİ
  3. HÜSEYİN SAYGIN
  4. AYDEMİR ASDEMİR SİVAS CUMHURİYET ÜNİVERSİTESİ
  5. İSMAİL EMRE ERGİN SİVAS CUMHURİYET ÜNİVERSİTESİ
  6. ABUZER ÖZTÜRK SİVAS CUMHURİYET ÜNİVERSİTESİ
  7. ARSLAN FATİH VELİBEYOĞLU
  8. ADEM KIR